Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Go Back to All Clinical Trials

Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Brief description of study

This is a prospective, randomized, placebo-controlled, multicenter study of patients with newly diagnosed glioblastoma (nGBM) to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide given together with locally administered sargramostim plus adjuvant oral temozolomide (TMZ) (Arm A) versus saline-Montanide emulsion with locally administered saline (instead of sargramostim) plus adjuvant oral temozolomide (TMZ) (Arm B).

Clinical Study Identifier: s22-00457

ClinicalTrials.gov Identifier: NCT05163080

Principal Investigator: Marissa Barbaro.

Other Investigators: Minerva A Utate, Maria Del Pilar Guillermo Prieto Eibl, Alexandra M. Miller, Sylvia Amor Tenefrancia Crispino, Erik P. Sulman, Lynda J Boulio, Joshua S. Silverman, Jonathan Tzu-l Yang.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies